C

Chernivtsi Regional Clinical Hospital | Pulmonology Department

Research site

(Unclaimed)

Location

137 Golovna Street, Chernivtsi, Chernivetska oblast, Ukraine

Site insights

Top conditions

Top treatments

Ozanimod

Methotrexate

Relamorelin

Docetaxel

Vinflunine

GLPG0634

Erdafitinib

GLPG0259

LY4268989

GB0139

Parent organization

This site is a part of Chernivtsi Regional Clinical Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting

Crohn's Disease

Drug: Mirikizumab

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting

Urothelial Cancer

Drug: Erdafitinib

Drug: Docetaxel

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Active, not recruiting

Severe Asthma

Drug: Placebo

Drug: Verekitug (UPB-101)

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderatel...

Begins enrollment this month

Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe

Drug: Placebo

Drug: LY4268989